The Prostate · 2007 · 30 citations · 35 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingGrowth Factor SignalingHormonal Cancer TherapyHormonal TherapyProstate CancerSteroid Hormone SignalingAndrogen Action In ProstateAndrogen PharmacologyAndrogen Receptor AgonistsAndrogen Receptor RegulationDrug Screening AssaysGreen Fluorescent Protein ReportersProstate Cancer Hormonal TherapyProstate Growth Regulation
BACKGROUND: We developed non-invasive, cell-based screening assays to rapidly and biologically assess factors that modulate prostate cancer growth and affect androgen receptor (AR) activity. METHODS: LNCaP cells, which stably express enhanced green fluorescent protein (EGFP) either constitutively or upon AR activation, were treated with a variety of agents, and then monitored by fluorescence and MTS assays for dose-dependent changes in cell number and AR activity. RESULTS: The assays were validated for rapid, fluorescence-based, quantitative measurement for the presence of growth and AR modulators. Using these assays, we found that osteoblast conditioned media (CM) enhanced prostate cancer cell growth, but not AR activity. After priming with androgen (<1 nM R1881), forskolin or the pesticide dichlorvos enhanced AR activation, whereas interleukin-6 (IL-6) inhibited it. CONCLUSION: These non-destructive, cell-based assays enable rapid systematic monitoring of the effects of drugs or complex mixtures on prostate cancer cell growth and/or AR activity.
35
G. David Roodman · New England Journal of Medicine · 2004 · 2.7K citations
Medicine, Oncology, Bone Metabolism +12
Shuk‐Mei Ho, Wan‐Yee Tang, Jessica Belmonte de Frausto et al. · Cancer Research · 2006 · 790 citations · Full text
Martin Gleave, Jer‐Tsong Hsieh, Chao Gao et al. · PubMed · 1991 · 452 citations
Medicine, Endocrinology, Oncology +17